REGEN BIOPHARMA, INC. (RGBP) Net margin 2017–2025
REGEN BIOPHARMA, INC. (RGBP) net profit margin by fiscal year — reported net income divided by reported revenue.
-282.5%FY2025 · since FY2017: -7046.0% → -282.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -282.5% | -771.4 pp |
| FY2024 | 488.9% | -544.1 pp |
| FY2023 | 1032.9% | +6422.8 pp |
| FY2022 | -5389.9% | -10969.6 pp |
| FY2021 | 5579.7% | +7964.4 pp |
| FY2020 | -2384.7% | +1901.8 pp |
| FY2019 | -4286.5% | +1552.5 pp |
| FY2018 | -5839.0% | +1207.0 pp |
| FY2017 | -7046.0% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RGBP financial trends
RGBP RevenueRGBP Net incomeRGBP Gross profitRGBP Gross marginRGBP Operating incomeRGBP Operating marginRGBP Operating cash flowRGBP Free cash flowRGBP Capital expendituresRGBP Return on equityRGBP Stock buybacksRGBP Dividends paidRGBP Total assetsRGBP Total liabilitiesRGBP Shareholders’ equityRGBP overview →